Phase 2 Study of a Vasopressin Receptor Antagonist in Children and Adolescents with Autism Spectrum Disorder (ASD)
The aV1ation Study
Sponsor: F. Hoffmann-La Roche Ltd Research Foundation
Enrolling: Male and Female Patients
Study Length: 39 Weeks
Clinic Visits: 16
IRB Number: WCMC 1609017599
U.S. Govt. ID: NCT02901431
Contact: Micah Davoren: 914-997-5587 /
Additional Study Information: The Translational Medicine Program at the Center for Autism and the Developing Brain is recruiting individuals with autism from 5 -17 years of age with an IQ over 70 to participate in our study called aV1ation. The purpose of this study is to test an investigational medicine that blocks a hormone receptor in the brain linked to the control of socialization, stress, anxiety and aggression. We want to see if this medicine is effective as a treatment to help improve social functioning in children with ASD. To determine this, participants will be randomly assigned to take the investigational drug or a placebo pill. Participation lasts up to 39 weeks and will involve regular visits to the Center for Autism and the Developing Brain. This will allow the study team to assess participants general health, social communication skills and social interaction skills. At the end of the 24 weeks, participants have the option to enter a 1-year extension, during which everyone will receive the investigational drug (even those who previously received a placebo). Participants will not have to pay for any study related treatments, lab tests, or assessments and will also be reimbursed $50 per visit.
This study is closed
Jeremy Veenstra-VanderWeele, MD
Do You Qualify?
Is your child between 5 and 17 years of age? Yes No
Does your child have a diagnosis of Autism Spectrum Disorder (ASD)? Yes No
Does your child have an IQ of at least 70? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Micah Davoren